Cell & Gene Therapy Innovation Speakers

Markus Karmasin

Head of Cell and Gene Therapy Germany

Novartis

Specialties includes pharmaceutical industry, marketing, and market access.

Pavlina Konstantinova

VP Research

uniQure N.V.

Dr. Pavlina Konstantinova is Vice President Research at uniQure, a gene therapy company focusing on orphan genetic diseases including HD.

Benoit Moreaux

Chief Scientific and Technological Officer

Bone Therapeutics

Benoit Moreaux brings 20 years of industry expertise in strategic operations planning and execution, as well as global quality assurance.

Sarah Snykers

QC Manager

Celyad

Sarah joined Celyad in 2015 to be at the offspring of a new exciting technology in the immunooncology field.

Christian van den Bos

Managing Director

Mares Ltd

Dr. van den Bos current developed technology and IP dramatically enhancing the efficacy of mesenchymal stem cells, the productivity of cell culture media for primary cells and a novel drug target

Laura Sepp-Lorenzino

Chief Scientific Officer

Intellia Therapeutics

Laura Sepp-Lorenzino, Ph.D. is Chief Scientific Officer of Intellia Therapeutics. In this role, she oversees all drug research across in vivo and ex vivo (engineered cell therapy) areas.

Marc Van Dijk

Vice President Platform Technology

AgenTus Therapeutics Ltd

Marc van Dijk, Ph.D. leads platform development for AgenTus and Agenus, and heads the Agenus UK site.

Maria Papathanasiou

Research Associate

Imperial College London

Dr Maria Papathanasiou is an appointed Lecturer at the Department of Chemical Engineering, Imperial College London (in effect April 2020).

Eric Halioua

President & Chief Executive Officer

PDC*line Pharma

Mr. Eric Halioua, MS, MBA, serves as President of the Board, Chief Executive Officer and President of PDC line Pharma SAS.

Jennifer murray

Managing Director/Past Chair

Life Science Group Ltd/International Serum Industry Association

Jenny has over 30 years’ experience in the cell culture industry in the UK and worldwide and a track record in building successful SMCs. Jenny is the current owner of Life Science Group Ltd (LSG).

Sean O Farrell

Senior Scientist Process Development & Manufacturing

GammaDelta

Masters in Medicine at King's College London

Ohad Karnieli

Founder and CEO

Adva Biotechnology

Dr. Karnieli earned his PhD in Biotechnology from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management.

Troels Jordansen

CEO

Glycostem Therapeutics

Troels has been part of management teams launching 3 cellular therapies across the world and raising in excess of €160 million.

Lior Raviv

Vice President Development

Pluristem Therapeutics

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development.

André G. Gerth

Chief Executive Officer

BioPlanta GmbH

André acts as Chief executive Officer Director of BioPlanta GmbH and FamiCord Deutschland GmbH.

Magdalena Tary-Lehmann

Chief Scientific Officer

Cellular Technology Limited

Magdalena is a Co-Founding Scientist and Chief Scientific Officer for CTL and Adjunct Associate Professor of Case Western Reserve University Department of Pathology.

Alain Vertès

Managing Director

NxR Biotechnologies GmbH

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland

Pamela Tranter

Head, Translational Research Group

UCL

Pamela joined UCL Translational Research Office (TRO) in 2014 and has been leading the Translational Research group since 2016.

Houria Bachtarzi

Senior Consultant in Gene and Cell Therapies

NDA Group AB

Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies

Otto-Wilhelm MERTEN

Gene Therapy and Vector Manufacturing Specialist

Miltenyi Biotec SAS

Otto-Wilhelm MERTEN has a degree in biotechnology (Ph.D.) from the University of Life Sciences in Vienna, holds an HDR at the University of Evry/Val-d’Essonne and is Visiting Professor at ITQB/UNL.

David Dobnik

Senior Research Associate

National Institute of Biology

Work in this field is mostly performed as contract research with partners from Europe and USA

Carmen Brenner

Quality Associate Director

Bone Therapeutics

PhD, Biomedical Science - Laboratory of Cancer Epigenetics

Marina Feschenko

Director, Analytical Development for Gene Therapy

Biogen

Dr. Marina Feschenko is currently a Principle Scientist at Biogen.

Darrin Disley

Chief Executive Officer

Mogrify Ltd

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started or invested in over 40 start-up life science, technology and social enterprises

Kyle Grant

Associate Director of Vector Production

Voyager

I am a classically trained chemical engineer with a deep understanding of molecular biology.

Paula Maria M. Alves

CEO

IBET

Paula M Alves holds a PhD in Biochemical Engineering from Instituto de Tecnologia Química Biológica da Universidade Nova de Lisboa.

Mio Muelthaler

Director, Business Development, Europe

Berkeley Lights

Mio Muelthaler is on a mission to spread the news about a new fascinating disruptive nanofluidics based single-cell technology for gene therapy in EU.

Annie Hubert

Senior Director of European Public Policy

Alliance for Regenerative Medicine

Annie brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access to the ARM Team.

Shibashish Giri

Deputy Head, Applied Stem Cell Biology and Cell Technology

University of Leipzig

Dr. Shibashish Giri has more than 12 years’ experience in preclinical research and clinical therapy for cell, tissue and organ regeneration in Germany.